Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Accrol Group Holdings Plc LSE:ACRL London Ordinary Share GB00BZ6VT592 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.65 2.74% 24.40 23.00 24.40 24.40 24.40 24.40 742 08:23:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Household Goods & Home Construction 136.6 -2.6 -1.1 - 78

Accrol Share Discussion Threads

Showing 851 to 871 of 1100 messages
Chat Pages: 44  43  42  41  40  39  38  37  36  35  34  33  Older
DateSubjectAuthorDiscuss
21/7/2021
08:35
Accrol (ACRL) full-year 2021 results presentation The full management team Dan Wright, Executive Chairman, Gareth Jenkins, CEO, Richard Newman, CFO and Graham Cox, Commercial Director give a comprehensive overview of the turnaround to date. Watch the video here: Https://www.piworld.co.uk/company-videos/accrol-acrl-full-year-2021-results-presentation/ Or listen to the podcast here: Https://piworld.podbean.com/e/accrol-acrl-full-year-2021-results-presentation/
tomps2
15/7/2021
08:24
Accrol Group Holdings (ACRL) full-year 2021 results webinar, today (15/07/21) at 1:15pm As part of the Group’s Financial Results roadshow, Dan Wright, Executive Chairman and Gareth Jenkins, CEO will present full year results followed by Q&A. Register here: Https://www.piworld.co.uk/events/
tomps2
14/7/2021
09:24
Acquisitions & Integrations Following the acquisition of LTC in November 2020, we have completed the integration of the business and expect to deliver annualised synergy benefits of GBP3.0m - three times greater than originally anticipated at the time of the acquisition. These are being driven through operational improvements across the wider group, including logistics, operational simplification, and procurement. The revenue synergies, which are measured over an agreed period of time, will be lower during this Period, due to the impact of the pandemic, but are expected to benefit the Group in the longer term In April 2021, the Group acquired the JD business in North Wales, a highly scalable flushable and bio-degradable wet wipe business. Early integration activities have progressed ahead of schedule and initial synergies are expected to be cGBP1m in the first full year of ownership. These will be delivered through operational synergies with the Group's existing facial tissue business, procurement benefits of the enlarged Group, simplification of organisation, and revenue growth opportunities, as the product offering to Accrol's existing customer base now includes its range of wet wipes. The Group's expectation with additional capital investment is to build a wet wipe business of significant scale by 2024.
zipstuck
14/7/2021
08:29
The numbers are ahead of consensus forecasts so I would not expect the share price to come to much harm from here. The manufacturing side of the business looks to be moving towards complete automation by 2023 and distortions to the demand for tissue paper are steadily working there way out of the system. Firm hold for me.
ygor705
14/7/2021
08:13
Directors to buy now results outI would think so (need to)
value viper
14/7/2021
07:57
What a load of waffle, ‘anticipated recovery’!
bookbroker
14/7/2021
07:54
Positive results statement ! "Despite the challenges of the pandemic, the Group was able to deliver on its strategic objectives. The business was successfully scaled, through the acquisition of Leicester Tissue Company and diversified via the John Dale wet wipes acquisition. The team's continued focus on operational efficiency delivered an overall improvement in reported gross margin of 580ppt to 27.7% and a tripling of initial expectations on LTC synergies. Adjusted EBITDA rose by 47% in the year to £15.6m. Despite the volatility created in the tissue market by the pandemic limiting the Group's revenue growth to 1.4% in the Period, Accrol outperformed its peers and increased its market share to 15.9% from 13.1% in FY21. Over the last 2 years the like for like sales (excluding Away from Home) have grown by 16% from £117.6m to £136.6m and market share growth for the Group has risen from 12% to 15.9%. With the business in excellent operational shape, scalable foundations for growth in place, and a strong market position, the Group is very well placed to benefit from the anticipated recovery in tissue volumes, as the effects of the pandemic unwind. The Group expects to see FY22 exit run rates to be significantly improved with the major discounters expecting uplift in tissue volumes and Accrol's recently secured additional new business has increased confidence for FY23 revenues and returns. Trading in line with forecasts in FY22 to date and the Board remains confident in the long-term prospects for Accrol"
masurenguy
14/7/2021
07:09
Dividend restored 0.5p
leadersoffice
13/7/2021
14:23
My gut feel - a buy now alsoWe will have to wait and see
value viper
13/7/2021
10:43
Still they sell, day before a trading update My short has this back at 30p before too long imo
investorsiba
13/7/2021
08:20
No way oversold Way too many sellers still further to drop imho
investorsiba
12/7/2021
14:29
Results webinar on Thursday: hTTps://www.piworld.co.uk/events/
ptolemy
12/7/2021
12:19
oversold - I agree.
ptolemy
09/7/2021
15:58
This is looking oversold and I like the synergy of the John Dale acquisition announced in April. With Premier Miton recently increasing their stake to 10%, plus results due next week, I'm back in today having exited @60p at the end of March.
masurenguy
09/6/2021
12:29
Technically the chart looks good for a move up. hTTps://twitter.com/SeymourTrading/status/1402587724540960776
ptolemy
02/6/2021
16:39
Ive been in the UK tissue Industry just over 40yrs now and I know the Tejanis and the guys at Natsons and the guys at Task and lots of mill Managers and owners and I dont often post on here for obvious reasons but when I read the diatribe above from Mr 1973 I tend to take the bait,I can tell you, he knows nothing about the tissue Industry and for balance knowing what I know I still hold and whilst disapointed the downside from here is minimal, as airbus says, its oversold.DYOR
stevieweebie2
02/6/2021
11:39
Its over sold now tbh, instead of selling my small holding, I'm buying more.
arbus5000
02/6/2021
07:01
I certainly wouldn't buy it now, out and staying out
stevesham
31/5/2021
13:07
Accrol have c15% of the uk market. Competition is inevitable and less efficient plants will close. Fwiw I took the hit and sold most at a loss last week. Decent enough company but better opportunities elsewhere
dr biotech
31/5/2021
07:49
yes that's correct: I do not think that Acroll have a monopoly position now, and this should prevent them from having that one the future.
arbus5000
31/5/2021
07:28
arbus5000 Thanks for filling in other details, the only thing I see that is good about this is lower prices for the consumers, which will have the adverse effect on Accrol, driving down prices and margins Be interesting to see how this impacts going forward
stevesham
Chat Pages: 44  43  42  41  40  39  38  37  36  35  34  33  Older
ADVFN Advertorial
Your Recent History
LSE
ACRL
Accrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221006 08:14:56